[go: up one dir, main page]

WO2024249307A1 - Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo - Google Patents

Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo Download PDF

Info

Publication number
WO2024249307A1
WO2024249307A1 PCT/US2024/031010 US2024031010W WO2024249307A1 WO 2024249307 A1 WO2024249307 A1 WO 2024249307A1 US 2024031010 W US2024031010 W US 2024031010W WO 2024249307 A1 WO2024249307 A1 WO 2024249307A1
Authority
WO
WIPO (PCT)
Prior art keywords
cd40l
tils
cell
cells
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/031010
Other languages
English (en)
Inventor
Vince LUCA
Daniel Abate DAGA
Renata Ariza Marques ROSSETTI
Patrick Hwu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center and Research Institute Inc
Original Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center and Research Institute Inc filed Critical H Lee Moffitt Cancer Center and Research Institute Inc
Publication of WO2024249307A1 publication Critical patent/WO2024249307A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • CD40 Cluster of differentiation 40
  • Preclinical studies have shown that activation of CD40 can evoke massive antineoplastic effects in several tumor models in vivo, providing a rationale for using CD40 agonists in cancer immunotherapy.
  • several potential agonistic antibodies that target CD40 have been investigated in clinical trials.
  • Early clinical trials have shown that the adverse events associated with agonists of CD40 thus far have been largely transient and clinically controllable, including storms of cytokine release, hepatotoxicity and thromboembolic events.
  • An antitumor effect of targeting CD40 for monotherapy or combination therapy has been observed in some tumors.
  • isolated CD40L monomers comprising a L259F substitution.
  • the isolated CD40L monomer of any preceding aspect further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K).
  • the isolated CD40L monomer can comprise SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.
  • Attorney Docket No: 10110-366WO1 [0005]
  • CD40L trimer constructs or CD40L dimer constructs comprising a trimer of a CD40L monomer including, but not limited to a CD40L monomer of any preceding aspect.
  • multimeric CD40 agonist constructs comprising two or more CD40L trimer constructs or two or more CD40L dimer constructs of any preceding aspect connected by a multimerization motif (such as for example, a leucine zipper or C-terminal domain of T4 fibritin (FOLDON) motif or Fc domain (including, but not limited to an IgA, IgG1, IgG2A, IgG2B, or IgG3 Fc domain).
  • the multimeric agonist can assemble with additional multimeric CD40 agonists to for a trimer of dimers (for example a trimer of leucine zipper CD40L dimers of a trimer of FOLDON CD40L dimers).
  • multimeric CD40 agonists of any preceding aspect comprising two CD40L trimeric constructs or three CD40L dimeric constructs of any preceding aspect wherein the trimeric construct comprises three CD40L monomers of any preceding aspect connected by a glycine-serine linker and wherein the dimeric constructs are connected by an immunoglobulin Fc domain (including, but not limited to an IgA, IgG1, IgG2A, IgG2B, or IgG3 Fc domain), thereby forming an Fc dimer of trimeric CD40L.
  • the multimeric CD40 agonist can dimerize through the presence of cysteine bonds.
  • multimeric CD40 agonists wherein the multimeric CD4 agonist is linked to a second CD40 agonist construct comprising an Fc dimer of trimeric CD40L thereby forming a tetramer of trimeric CD40L.
  • the multimeric CD40L does not require antibody crosslinking.
  • vectors encoding the CD40L monomer of any preceding aspect, the CD40L trimer construct of any preceding aspect, the CD40L dimeric construct of any preceding aspect, and/or the multimeric CD40 agonist of any preceding aspect as well as cells (such as, for examples, tumor infiltrating lymphocyte, feeder cell, B cell, natural killer cell, chimeric antigen receptor (CAR) T cell, CAR NK cell CAR macrophage (CARMA), or dendritic cell) comprising said vectors, CD40L monomers, Cd40L trimer constructs, the CD40L dimeric constructs, or multimeric CD40 agonists.
  • cells such as, for examples, tumor infiltrating lymphocyte, feeder cell, B cell, natural killer cell, chimeric antigen receptor (CAR) T cell, CAR NK cell CAR macrophage (CARMA), or dendritic cell
  • TILs tumor infiltrating lymphocytes
  • methods of expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo comprising obtaining TILs and culturing the TILs in media comprising one or more of the isolated CD40L monomers of any preceding aspect, one or more CD40L trimer constructs of any preceding aspect, one or more CD40L dimeric Attorney Docket No: 10110-366WO1 construct of any preceding aspect, one or more of the multimeric CD40 agonists of any preceding aspect, the vector of any preceding aspect, or the cell of any preceding aspect.
  • TILs tumor infiltrating lymphocytes
  • methods of expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo comprising obtaining TILs and culturing the TILs in media comprising one or more of the isolated CD40L monomers comprising a L259F substitution (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40L monomer as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8), one or more of the CD40L trimer constructs, one or more CD40L dimeric constructs, and/or one or more CD40
  • TILs of any preceding aspect are methods of expanding TILs of any preceding aspect, wherein the TILs are cultured in a gas permeable reservoir.
  • methods of treating, decreasing, inhibiting, reducing, ameliorating and/or preventing a cancer and/or metastasis in a subject comprising administering to the subject the expanded TILs of any preceding aspect.
  • TILs tumor infiltrating lymphocytes
  • methods of treating, decreasing, inhibiting, reducing, ameliorating and/or preventing a cancer and/or metastasis in a subject comprising administering to the subject comprising obtaining tumor infiltrating lymphocytes (TILs) from the subject; culturing the TILs in media comprising one or more of the isolated CD40L monomers comprising a L259F substitution (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40L monomer as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8), one or more
  • chemokine (C-C motif) ligand 2 CCL2
  • CCL3 CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18)
  • CCL19 CCL21
  • chemokine (C-X-C motif) ligand 9 CXCL9
  • CXCL10 CXCL11, and CXCL13 in tumor cells
  • comparing the tumor gene expression levels to reference gene expression levels and identifying a subject who has tumor gene expression levels above the reference gene expression levels.
  • TILs tumor infiltrating lymphocytes
  • TILs tumor infiltrating lymphocytes
  • a subject with a tumor comprising administering one or more of the isolated CD40L monomers comprising a L259F substitution (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40L monomer as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8), one or more of the CD40L trimer constructs, one or more CD40L dimeric constructs, and/or one or more CD40 agonists (such as, for example, CD40L including, but not limited to multimeric CD40
  • a L259F substitution including
  • FIG. 1 shows TIL enhancement via ex vivo stimulation with CD40 agonists.
  • FIG. 2A and 2B show TIL expansion from melanoma digests is improved by CD40 stimulation. Frozen tumor digests were cultured in presence of high-dose IL-2 (control) or high-dose IL-2 plus a CD40 agonist (for 4 weeks.
  • FIGS. 3A and 3B show melanoma tumors contain B cells, which can be activated using a CD40 agonist.
  • Figure 3A shows frozen tumor digests were analyzed for the presence of B cells (CD19+) and myeloid cells (HLA-DR hi ). The vast majority of B cells expressed CD40, while half of myeloid cells did.
  • Figure 3B shows tumor digests were cultured for two days in presence of standard TIL expansion media (Ctrl.) or the same media supplemented with a CD40 agonist (CD40 stim).
  • FIG. 4 shows TIL expansion from melanoma digests is improved by CD40 stimulation. Frozen tumor digests were cultured in presence of high-dose IL-2 (control) or high-dose IL-2 plus a CD40 agonist (for 4 weeks. The total number of live cells, CD4+ T lymphocytes, and of CD8+ lymphocytes was significantly increased in the CD40 stimulated group. *p ⁇ 0.05.
  • Figures 5A and 5B show that CD40 stimulation results in increased Effector Memory cells, and increased CD39- cells in 3/5 cases.
  • Frozen tumor digests were cultured in presence of high-dose IL-2 (control) or high-dose IL-2 plus a CD40 agonist (for 4 weeks.
  • Figure 5A shows analysis of differentiation phenotype based on CD45RA and CCR7 expression.
  • Figure 5B shows expression of CD39 and CD69 in the CD4 T cell compartment. *p ⁇ 0.05.
  • Figure 6 shows TIL growth. The number of NSCLC samples in which TIL expanded vs not expanded. Patient Samples from NSCLC were dissociated, and TIL expanded in conditions containing IL-2 or IL-2 + CD40L.
  • FIG. 7 shows the expansion of TIL and CD4 CD8 phenotype.
  • Patient Samples from NSCLC were dissociated, and TIL expanded in conditions containing IL-2 or IL-2 + CD40L. Absolute number of TIL expanded was compared as well as CD4 and CD8 percentages as analyzed by flow cytometry.
  • Attorney Docket No: 10110-366WO1 [0022]
  • Figure 8 shows the stem like and exhausted phenotype. TIL expanded from NSCLC samples with IL-2 or IL-2 + CD40L were analyzed for (A) stem like markers (CD39- CD69-) and (B) exhausted markers (CD39+ CD69+) by flow cytometry.
  • Figure 9 shows TIL Reactivity.
  • TIL from NSCLC samples expanded in IL-2 or IL-2 + CD40L were co-cultured with dissociated autologous tumor cells at a ratio of 1:1.
  • An MHC-I blocking antibody was used for analysis of MHC-I specificity of reaction.
  • supernatant was collected and analyzed for Granzyme B, IFN ⁇ , and TNF ⁇ expression by use of the Protein Simple ELLA platform.
  • Figure 10 shows yeast display selections: isolation of a CD40L clone with enhanced expression and CD40 binding.
  • Figure 11 shows a sequence alignment for residues 115-280 of CD40L wildtype (CD40L_WT)(SEQ ID NO: 1) and CD40L variants CD40L_EPC1 (SEQ ID NO: 2), CD40L_EPC3 (SEQ ID NO: 3), CD40L_EPC10 (SEQ ID NO: 4), CD40L_EPC9 (SEQ ID NO: 5), CD40L_EPC7 (SEQ ID NO: 6), CD40L_EPC6 (SEQ ID NO: 7), and CD40L_EPC9 (SEQ ID NO: 8).
  • Figure 12 shows a structural analysis of CD40L variants and that the most promising variants have mutations at trimer and receptor binding interfaces.
  • Figures 13A and 13B show the thermostability of CD40L variants.
  • Figure 13C shows the substitutions of CD40L for variants CD40L_EPC6 (SEQ ID NO: 7), CD40L_EPC1 (SEQ ID NO: 2), CD40L_EPC7 (SEQ ID NO: 6), CD40L_EPC10 (SEQ ID NO: 4) at residues 115-261 relative to (CD40L_WT)(SEQ ID NO: 1).
  • Figures 14A and 14B show the evaluation of affinity-matured CD40L constructs. A) B-cell stimulation curve comparing affinity-matured CD40L monomers.
  • Peripheral blood B cells from a healthy donor were cultured for 48 hours in presence of different concentrations of the affinity-matured CD40L constructs, and a secondary antibody to induce multimerization. Curves represent the percentage of CD80+CD86+ B cells. A commercially available CD40L trimer (0.043 uM) was used as a positive control (dotted line).
  • MFI mean fluorescence intensity
  • FIG. 10110-366WO1 lymphoid single, viable, CD3- CD19+ cells. Cells stained with the secondary antibody alone were used as negative control.
  • WT wild-type monomer.
  • Figure 15 shows lung TIL expansion with affinity-matured CD40L constructs. Lung tumor fragments were cultured in standard TIL expansion media (Control) or supplemented with different CD40L molecules (0.043uM) for 3-4 weeks. An anti-His antibody was used to cross-link the molecules.
  • Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed.
  • a particular data point “10” and a particular data point 15 are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed. [0034] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. [0035] A "decrease" can refer to any change that results in a smaller amount of a symptom, disease, composition, condition, or activity.
  • a substance is also understood to decrease the genetic output of a gene when the genetic output of the gene product with the substance is less relative to the output of the gene product without the substance.
  • a decrease can be a change in the symptoms of a disorder such that the symptoms are less than previously observed.
  • a decrease can be any individual, median, or average decrease in a condition, symptom, activity, composition in a statistically significant amount.
  • the decrease can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% decrease so long as the decrease is statistically significant.
  • “Inhibit,” “inhibiting,” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. [0037] By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant lowering of an event or characteristic (e.g., tumor growth).
  • an event or characteristic e.g., tumor growth
  • Treatment include the administration of a composition with the intent or purpose of partially or completely preventing, delaying, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing, mitigating, and/or reducing the intensity or frequency of one or more a diseases or conditions, a symptom of a disease or condition, or an underlying cause of a disease or condition.
  • Treatments according to the invention may be applied preventively, prophylactically, pallatively or remedially.
  • Prophylactic treatments are administered to a subject prior to onset (e.g., before obvious signs of cancer), during early onset (e.g., upon initial signs and symptoms of cancer), or after an established development of cancer. Prophylactic administration can occur for day(s) to years prior to the manifestation of symptoms of an infection.
  • preventing or other forms of the word, such as “preventing” or “prevention,” is meant to stop a particular event or characteristic, to stabilize or delay the development or progression of a particular event or characteristic, or to minimize the chances that a particular event or characteristic will occur. Prevent does not require comparison to a control as it is typically more absolute than, for example, reduce. As used herein, something could be reduced but not prevented, but something that is reduced could also be prevented.
  • Biocompatible generally refers to a material and any metabolites or degradation products thereof that are generally non-toxic to the recipient and do not cause significant adverse effects to the subject.
  • Comprising is intended to mean that the compositions, methods, etc. include the recited elements, but do not exclude others. "Consisting essentially of'' when used to define compositions and methods, shall mean including the recited elements, but excluding other elements of any essential significance to the combination.
  • compositions consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like.
  • a “control” is an alternative subject or sample used in an experiment for comparison purposes. A control can be "positive” or “negative.”
  • the term “subject” refers to any individual who is the target of administration or treatment.
  • the subject can be a vertebrate, for example, a mammal.
  • the subject can be human, non-human primate, bovine, equine, porcine, canine, or feline.
  • the subject can also be a guinea pig, rat, hamster, rabbit, mouse, or mole.
  • the subject can be a human or veterinary patient.
  • patient refers to a subject under the treatment of a clinician, e.g., physician.
  • Effective amount” of an agent refers to a sufficient amount of an agent to provide a desired effect.
  • an “effective amount” of an agent can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
  • An “effective amount” of an agent necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response.
  • a "pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a pharmaceutical formulation provided by the disclosure and administered to a subject as described herein without causing significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained.
  • the term When used in reference to administration to a human, the term generally implies the component has met the required standards of toxicological and manufacturing testing or Attorney Docket No: 10110-366WO1 that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
  • “Pharmaceutically acceptable carrier” means a carrier or excipient that is useful in preparing a pharmaceutical or therapeutic composition that is generally safe and non-toxic and includes a carrier that is acceptable for veterinary and/or human pharmaceutical or therapeutic use.
  • carrier or “pharmaceutically acceptable carrier” can include, but are not limited to, phosphate buffered saline solution, water, emulsions (such as an oil/water or water/oil emulsion) and/or various types of wetting agents.
  • carrier encompasses, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer, or other material well known in the art for use in pharmaceutical formulations and as described further herein.
  • “Pharmacologically active” (or simply “active”), as in a “pharmacologically active” derivative or analog, can refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.
  • “Therapeutic agent” refers to any composition that has a beneficial biological effect.
  • Beneficial biological effects include both therapeutic effects, e.g., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, e.g., prevention of a disorder or other undesirable physiological condition (e.g., a non-immunogenic cancer).
  • the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, proagents, active metabolites, isomers, fragments, analogs, and the like.
  • “therapeutic agent” refers to an amount that is effective to achieve a desired therapeutic result.
  • a desired therapeutic result is the control of type I diabetes.
  • a desired therapeutic result is the control of obesity.
  • Therapeutically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated Attorney Docket No: 10110-366WO1 and the age, gender, and weight of the subject.
  • the term can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect, such as pain relief.
  • the precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the agent and/or agent formulation to be administered (e.g., the potency of the therapeutic agent, the concentration of agent in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.
  • treatment refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder.
  • This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
  • this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
  • CD40L monomers are a protein that is primarily expressed as a trimer of CD40L monomers on T cells. CD40L acts as a costimulatory molecule and promotes B cell maturation.
  • CD40L monomers comprising a leucine to phenylalanine substitution at residue 259 (i.e., a L259F substitution). The substitution at residue 259 occurs at the trimer interface for CD40L and can result in great stability of the trimer.
  • the disclosed CD40L monomer can comprise additional substitutions at one or more of residue 133, residue 139, residue 185, residue 217, residue 240, and/or residue 274.
  • the CD40L monomer can comprise a lysine to threonine substitution at residue 133 (K133T), a glutamine to histidine or lysine substitution at residue 139 (i.e., a Q139H or Q139K substitution), a serine to glycine substitution at residue 185 (i.e., a S185G substitution), a proline to histidine or arginine substitution (i.e., a P217H or P217R substitution), an asparagine to lysine substitution at residue 240 (i.e., a N240K substitution), and/or a glutamate to lysine substitution at residue 274 (i.e., a E274K substitution).
  • the isolated CD40L monomer can comprise SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8.
  • CD40L trimer constructs comprising a trimer of any of the CD40L monomers disclosed herein. Attorney Docket No: 10110-366WO1 C.
  • Multimeric CD40 agonists [0054] It is understood and herein contemplated that the CD40 agonists used to expand TILs are not limited the CD40L and anti-CD40 antibodies, but can comprise novel constructs and expression systems including, multimeric CD40L.
  • multimeric CD40 agonist constructs comprising two or more CD40L trimer constructs comprising CD40L monomer including, but not limited to, any of the CD40L monomers disclosed herein, said trimer constructs connected by a multimerization motif (such as for example, a leucine zipper or C-terminal domain of T4 fibritin (FOLDON) motif or Fc domain (including, but not limited to an IgA, IgG1, IgG2A, IgG2B, or IgG3 Fc domain).
  • a multimerization motif such as for example, a leucine zipper or C-terminal domain of T4 fibritin (FOLDON) motif or Fc domain
  • the multimeric CD40L can comprise a dimer of CD40L monomers (such as, for example, GDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYI YAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFE LQPGASVFVNVTDPSQVSHGTGFTSFGLLKLT (SEQ ID NO: 12)) linked by a linker.
  • GDQNPQIAAHVISEASSKTTSVLQWAEKGYYTMSNNLVTLENGKQLTVKRQGLYYI YAQVTFCSNREASSQAPFIASLCLKSPGRFERILLRAANTHSSAKPCGQQSIHLGGVFE LQPGASVFVNVTDPSQVSHGTGFTSFGLLKLT (SEQ ID NO: 12)) linked by a linker.
  • the multimeric agonist can assemble with additional multimeric CD40 agonists to for a trimer of dimers (for example a trimer of leucine zipper CD40L dimers (SEQ ID NO: 9) or a trimer of FOLDON CD40L dimers (SEQ ID NO: 10)).
  • the multimeric CD40 agonists can comprise two CD40L trimeric constructs wherein the trimeric construct comprises three CD40L monomers connected by a glycine-serine linker and wherein the dimeric constructs are connected by an immunoglobulin Fc domain (such as, for example, SEQ ID NO: 11) thereby forming an Fc dimer of trimeric CD40L.
  • the Fc domain can comprise any mammalian Fc domain, including, but not limited to a human IgA, IgG1, IgG2A, IgG2B, or IgG3 Fc domain.
  • the multimeric CD40 agonist can dimerize through the presence of cysteine bonds.
  • disclosed herein are multimeric CD40 agonists, wherein the multimeric CD4 agonist is linked to a second CD40 agonist construct comprising an Fc dimer of trimeric CD40L thereby forming a tetramer of trimeric CD40L.
  • CD40L monomers, CD40L trimer constructs, CD40L dimer constructs, and/or multimeric CD40L trimer constructs can be encoded on a vector and either expressed by the vector or integrated into a cell genome and expressed by a cell or a vector in said cell.
  • TILs Tumor infiltrating lymphocytes
  • cells such as, for examples, tumor infiltrating lymphocyte, feeder cell, B cell, natural killer cell, Attorney Docket No: 10110-366WO1 chimeric antigen receptor (CAR) T cell, CAR NK cell CAR macrophage (CARMA), or dendritic cell
  • CAR chimeric antigen receptor
  • CARMA CAR NK cell CAR macrophage
  • dendritic cell dendritic cell
  • TILs have been used in autologous adaptive transfer therapy for the treatment of cancer.
  • a fresh surgically resected tumor is used as the starting material for successful initiation and expansion of tumor specific TIL culture to manufacture a clinically relevant dose of TIL therapy. Therefore, the candidate patient for TIL therapy needs to be eligible for surgery. If the patient is eligible for surgery, the tumor needs to be resectable. If several tumor anatomical sites are present, a skilled choice of resection of the suitable tumor sites with potential T cell infiltration must be made for each patient.
  • TILs In the production of TILs, once a surgically resectable tumor has been obtained, 5-7 weeks of culture are needed and the culture conditions necessitate the use of a cleanroom, splitting of cultures to check confluence, and considerable time to maintain the cells. Disclosed herein are more rapid methods of expanding TILs.
  • TILs tumor infiltrating lymphocytes
  • methods of expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo comprising obtaining TILs and culturing the TILs in media comprising one or more of the isolated CD40L monomers comprising a L259F substitution disclosed herein (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40L monomer as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8), one or more of the CD40L trimer constructs disclosed herein, one or more CD40L dimer constructs disclosed herein
  • TILs tumor infiltrating lymphocytes
  • methods of expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo comprising obtaining TILs and culturing the TILs in media comprising one or more of the isolated CD40L monomers comprising a L259F substitution (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 Attorney Docket No: 10110-366WO1 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40L monomer as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8), one or more of the CD40L trimer constructs, one or more CD40L di
  • TILs tumor infiltrating lymphocytes
  • methods of expanding tumor infiltrating lymphocytes (TILs) in a subject with a tumor comprising administering to the subject at the site of the tumor any one or more of the isolated CD40L monomers comprising a L259F substitution (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40L monomer as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8), one or more of
  • TILs tumor infiltrating lymphocytes
  • a tumor infiltrating lymphocytes comprising administering one or more CD40 agonists (such as, for example, CD40L including, but not limited to multimeric CD40L as well as CD40 agonists expressed or overexpressed by a cell (such as, for examples, tumor infiltrating lymphocyte, feeder cell, B cell, natural killer cell, chimeric antigen receptor (CAR) T cell, CAR NK cell CAR macrophage (CARMA), or dendritic cell)) to the subject at the site of the tumor.
  • CD40 agonists such as, for example, CD40L including, but not limited to multimeric CD40L as well as CD40 agonists expressed or overexpressed by a cell (such as, for examples, tumor infiltrating lymphocyte, feeder cell, B cell, natural killer cell, chimeric antigen receptor (CAR) T cell, CAR NK cell CAR macrophage (CARMA), or dendritic cell)
  • the TILs are obtained from a biopsy (such as, for example, core biopsies and/or one or more surgical resections) of a surgically resectable tumor.
  • the disclosed methods of producing an expanded TIL Attorney Docket No: 10110-366WO1 population comprise obtaining one or more biopsies from the subject (such as, for example, percutaneous tumor samples).
  • biopsy can include any partial removal of a tissue such as excisional, incisional, core, or fine needle aspiration biopsies.
  • TILs obtained from biopsies such as, for example, core biopsies including core needle biopsies
  • core biopsies such as, for example core needle biopsies
  • core biopsies are used as the source of the tissue sample
  • core biopsies such as, for example core needle biopsies
  • core biopsies can be obtained using any device with which a core biopsy can be obtained (see, for example, the Bard Core Biopsy Instruments and Temno Biopsy Systems by Carefusion such as, BARD MAGNUM®, BARD MAX-CORE®, BARD BIOPTY-CUT®, BARD MARQUEE®, BARD MISSION®, and BARD MONOPTY® from CR Bard, Inc.).
  • the needle for obtaining the biopsy can be 6, 8, 10, 12, 14, 16, 18, or 20 gauge needle with a needle length between about 2cm and to about 30cm long, preferably between about 10cm and about 25 cm long, more preferably between about 16cm and about 20cm long.
  • the needle length for obtaining a core biopsy can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30cm long.
  • the penetration depth of the needle can be between about 15mm and 30mm, preferably between about 20mm and 25 mm.
  • the penetration depth can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30mm.
  • the use of core biopsy allows the ability to target certain and possibly multiple areas of a tumor.
  • methods of rapidly producing an expanded TIL population further comprising the use of imaging techniques such as radiomics to guide TIL acquisition.
  • tissue samples including, but not limited to biopsies (such as, for example, core biopsies including core needle biopsies) and/or surgical resections provide the added advantage of not requiring further sectioning (i.e., making fragments), but can be directly digested.
  • the disclosed methods can comprise placing the tissue sample directly into a digesting solution (such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of Attorney Docket No: 10110-366WO1 collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®)).
  • a digesting solution such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of Attorney Docket No: 10110-366WO1 collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®)).
  • the tumor cells can be dissociated using mechanical fragmentation (either pool
  • TILs tumor infiltrating lymphocytes
  • the one or more core biopsies are digested directly from the patient without disaggregation of the specimen.
  • Digests are well known in the art and typically comprise a collagenase, hyaluronidase, and DNAse. It is understood and herein contemplated that the digest can comprise at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®).
  • collagenase e.g., XIAFLEX®
  • hyaluronidase e.g., HYLENEX®
  • DNAse e.g., PULMOZYME®
  • the digest can occur directly from the tissue sample without prior fragmentation (mechanical or otherwise) or the separation or pooling of fragments thereby creating a bulk non-purified digest.
  • concentration of fragmented and/or digested cells used in the pre-REP of the disclosed methods can affect the yield and or efficacy of the disclosed methods.
  • the methods utilizes less than 5x10 6 cells, for example, the method can use 4x10 6 , 3x10 6 , 2x10 6 , 1x10 6 , 9x10 5 , 8x10 5 , 7x10 5 , 6x10 5 , 5x10 5 , 4x10 5 , 3x10 5 , 2x10 5 , or 1x10 5 or less bulk non-purified digest cells per tissue culture well.
  • the methods utilizes less than 5x10 6 cells, for example, the method can use 4x10 6 , 3x10 6 , 2x10 6 , 1x10 6 , 9x10 5 , 8x10 5 , 7x10 5 , 6x10 5 , 5x10 5 , 4x10 5 , 3x10 5 , 2x10 5 , or 1x10 5 or less bulk non-purified digest cells per tissue culture well.
  • Also disclosed herein are methods of expanding TILs, further adding autologous B cells to the culture of TILs and CD40L
  • TILs tumor infiltrating lymphocytes
  • CD40 agonists such as, for example, a CD40 ligand (CD40L) and/or anti-CD40 antibody
  • CD40 antigen is intended a glycosylated transmembrane peptide or any fragment thereof (GenBank Accession No. X60592; U.S. Pat. Nos.5,674,492 and 4,708,871; Stamenkovic et al.
  • the CD40 receptor is displayed on the surface of a variety of cell types, as described elsewhere herein. By “displayed on the surface” and “expressed on the surface” is intended that all or a portion of the CD40 antigen is exposed to the exterior of the cell. The displayed or expressed CD40 antigen may be fully or partially glycosylated. Attorney Docket No: 10110-366WO1 [0071] By “agonist activity” is intended that the substance functions as an agonist.
  • An agonist combines with a receptor on a cell and initiates a reaction or activity that is similar to or the same as that initiated by the receptor's natural ligand.
  • An agonist of CD40 induces any or all of, but not limited to, the following responses: B-cell proliferation and differentiation, antibody production, intercellular adhesion, B-cell memory generation, isotype switching, up- regulation of cell-surface expression of MHC Class II and CD80/86, and secretion of pro- inflammatory cytokines such as IL-8, IL-12, and TNF.
  • antagonist activity is intended that the substance functions as an antagonist.
  • An antagonist of CD40 prevents or reduces induction of any of the responses induced by binding of the CD40 receptor to an agonist ligand, particularly CD40L.
  • the antagonist may reduce induction of any one or more of the responses to agonist binding by 5%, 10%, 15%, 20%, 25%, 30%, 35%, preferably 40%, 45%, 50%, 55%, 60%, more preferably 70%, 80%, 85%, and most preferably 90%, 95%, 99%, or 100%.
  • B-cell proliferation assays include, but are not limited to, B-cell proliferation assays, Banchereau-Like-B-Cell proliferation assays, T-cell helper assays for antibody production, co-stimulation of B-cell proliferation assays, and assays for up- regulation of B-cell activation markers.
  • B-cell proliferation assays include, but are not limited to, Banchereau-Like-B-Cell proliferation assays, T-cell helper assays for antibody production, co-stimulation of B-cell proliferation assays, and assays for up- regulation of B-cell activation markers.
  • T-cell helper assays for antibody production
  • co-stimulation of B-cell proliferation assays include, but are not limited to, T-cell helper assays for antibody production, co-stimulation of B-cell proliferation assays, and assays for up- regulation of B-cell activation markers.
  • a substance “free of significant agonist activity” would exhibit an agonist activity of not more than about 25% greater than the agonist activity induced by a neutral substance or negative control, preferably not more than about 20% greater, 15% greater, 10% greater, 5% greater, 1% greater, 0.5% greater, or even not more than about 0.1% greater than the agonist activity induced by a neutral substance or negative control as measured in an assay of a B-cell response.
  • the antagonist anti-CD40 antibodies useful in the methods of the present invention are free of significant agonist activity as noted above when bound to a CD40 antigen on a normal human B cell. In one embodiment of the invention, the antagonist anti-CD40 antibody is free of significant agonist activity in one B-cell response.
  • the antagonist anti-CD40 antibody is free of significant agonist activity in assays of more than one B-cell response (e.g., proliferation and differentiation, or proliferation, differentiation, and antibody production).
  • B-cell response e.g., proliferation and differentiation, or proliferation, differentiation, and antibody production.
  • anti-CD40 antibody encompasses any antibody that specifically recognizes the CD40 B-cell surface antigen, including polyclonal antibodies, monoclonal antibodies, single-chain antibodies, and fragments thereof such as Fab, F(ab′)2, Fv, and other fragments which retain the antigen binding function of the parent anti-CD40 antibody. Polyclonal sera may be prepared by conventional methods.
  • a solution containing the CD40 antigen is first used to immunize a suitable animal, preferably a mouse, rat, rabbit, or goat. Rabbits or goats are preferred for the preparation of polyclonal sera due to the volume of serum obtainable, and the availability of labeled anti-rabbit and anti-goat antibodies.
  • Polyclonal sera can be prepared in a transgenic animal, preferably a mouse bearing human immunoglobulin loci.
  • Sf9 cells expressing CD40 are used as the immunogen.
  • Immunization can also be performed by mixing or emulsifying the antigen-containing solution in saline, preferably in an adjuvant such as Freund's complete adjuvant, and injecting the mixture or emulsion parenterally (generally subcutaneously or intramuscularly). A dose of 50-200 ⁇ g/injection is typically sufficient. Immunization is generally boosted 2-6 weeks later with one or more injections of the protein in saline, preferably using Freund's incomplete adjuvant. One may alternatively generate antibodies by in vitro immunization using methods known in the art, which for the purposes of this invention is considered equivalent to in vivo immunization.
  • an adjuvant such as Freund's complete adjuvant
  • Polyclonal antisera are obtained by bleeding the immunized animal into a glass or plastic container, incubating the blood at 25° C. for one hour, followed by incubating at 4° C. for 2-18 hours.
  • the serum is recovered by centrifugation (e.g., 1,000 ⁇ g for 10 minutes).
  • About 20-50 ml per bleed may be obtained from rabbits.
  • the methods can further comprise the use of IL-2 in the culture. It is understood and herein contemplated that the concentration of the IL-2 can be adjusted to maximize the expansion of TILs.
  • the IL-2 concentration used to culture TILs can be 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000 IU/mL or more.
  • the culture process employed by the art understood methods takes 5-7 weeks to expand TILs from bulk non-purified tumor digests. This is a significant problem in the art as additional time to initiating adoptive transfer therapy of TILs represents an increased risk to the patient due to progression of malignancy while the cell product is being prepared.
  • the present method decreases the expansion time to less than 5 weeks resulting in decreased attrition patients from therapy secondary to disease progression.
  • culturing to obtain an expanded population of TILs can occur for any time between 1 day and 5 weeks (35 days), preferably between 21 days (3 weeks) and 5 weeks (35 days), more preferably between 4 weeks (28 days) and 5 weeks (35 days).
  • the culture time can be less than 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days.
  • the pre-REP expansion is harvested when the desired expansion is reached, but not more than 4 weeks.
  • TIL expansion methods wherein the pre-REP culture is 1, 2, 3, 4, 5, 6, 7 (1 week) ,8, 9, 10, 11, 12, 13, 14 (2 weeks), 15, 16, 17, 18, 19, 20, 21 (3 weeks), 22, 23, 24, 25, 26, 27, or 28 (4 weeks) days.
  • the REP can occur for 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days between 1 and 3 days, between 3 and 5 days, between 3 and 7 days, between 3 and 11 days, between 3 and 14 days, between 5 and 7 days, between 5 and 11 days, between 5 and 14 days, between 7 and 11 days, between 7 and 14 days, at least 7 days, at least 11 days, or at least 14 days.
  • the pre-REP TIL can be frozen and used at a later time.
  • the fresh or thawed pre-REP TIL are submitted to a rapid expansion protocol (REP) can occur for 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days between 1 and 3 days, between 3 and 5 days, between 3 and 7 days, between 3 and 11 days, between 3 and 14 days, between 5 and 7 days, between 5 and 11 days, between 5 and 14 days, between 7 and 11 days, between 7 and 14 days, at least 7 days, at least 11 days, or at least 14 days.
  • the TILs can be thawed for 1-3 days.
  • a second culture of thawed TILs can be used to augment the number of TILs.
  • the exchange of media can comprise 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% removal and replacement of media. This media exchange can be accomplished employing any acceptable method for proper tissue culture maintenance known in the art.
  • the media exchange can occur at least one time during the culture of the TILs.
  • the media in the reservoir can be exchanged 1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, Attorney Docket No: 10110-366WO1 30, 31, 32, 33, 34, or 35 times during the culture period. That is, the media exchange can occur once during the culture period, once every 15 days, once every 10 days, once every 7 days, once every 5 days, once every other day, or about 2 to 3 times per week.
  • the culture methods employed herein can utilize any complete media comprising IL-2 appropriate for the growth and propagation of the TILs, including, but not limited to Minimum Essential Medium (MEM), Eagles’s Minimum Essential Medium (EMEM), Dulbecco’s Minimum Essential Medium (DMEM) Medium 199, RPMI 1640, CMRL-1066, BGJb Medium, Iscove’s Modified Dulbecco’s Medium (IMDM), and Blood Cell Media.
  • MEM Minimum Essential Medium
  • EMEM Minimum Essential Medium
  • DMEM Minimum Essential Medium
  • RPMI 1640 RPMI 1640
  • CMRL-1066 CMRL-1066
  • BGJb Medium Iscove’s Modified Dulbecco’s Medium
  • IMDM Blood Cell Media.
  • the TILs can be cultured in any gas permeable reservoir suitable for cell culture and the expansion of TILs. In one aspect, it is understood and herein contemplated that large tissue culture flasks can slow down the expansion of TILs as it takes longer
  • the gas permeable reservoir can be a tissue culture plate comprising 6 (approximately 10cm 2 surface area per well and 60cm 2 total surface area), 12(approximately 4cm 2 surface area per well and approximately 48cm 2 total surface area), 24 (approximately 2cm 2 surface area per well and approximately 48cm 2 total surface area), 48(approximately 1cm 2 surface area per well and approximately 48cm 2 total surface area), or 96 (approximately 0.32cm 2 surface area per well and 31cm 2 total surface area) wells (for example, G-Rex24 well plate or G-Rex6 well plate manufactured by Wilson Wolf).
  • the plates can be silicone coated.
  • TIL population can become terminally exhausted no longer being able to exert its effector function.
  • the presently described culture methods can shift the percentage of terminally exhausted T cells to stem-like T cells which have more effector potential.
  • terminally exhausted T cells refers to T cells classically being CD39+ and CD69+ T cells.
  • the cells can include a higher percentage of one or more of PD- 1, CTLA-4, LAG3, TIM-3, TIGIT, BTLA, 2B4, CD160 and a loss or decrease in TCF-1 expression.
  • stem-like refers to T cells that are CD39-CD69- T cells.
  • Stem- like T cells can also be characterized as CCR7+ CD45RA+ CD95+ or CCR7+ CD62L+ CD45RA+ CD45RO- CD95+.
  • Stem-like cells can also include expression or one or more of CD28, CD27, IL-7Ra, CD11a, IL-2Rb, CD58, CD122, CXCR3, CD31, CD127, and TCF1.
  • a method of increasing the proportion of Stem- like CD8 T cells in a population of TILs in vitro or ex vivo comprising obtaining TILs and culturing the TILs in media comprising one or more CD40 agonists (such as, for example, a CD40 ligand (CD40L) monomer as disclosed herein, a CD40L dimer as disclosed herein, a CD40L trimer as disclosed herein, a CD40L multimer as disclosed herein, and/or anti-CD40 antibody).
  • CD40 agonists such as, for example, a CD40 ligand (CD40L) monomer as disclosed herein, a CD40L dimer as disclosed herein, a CD40L trimer as disclosed herein, a CD40L multimer as disclosed herein, and/or anti-CD40 antibody.
  • the TILs can be cultured for at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days.
  • the TILs are obtained from a biopsy (such as, for example, core biopsies and/or one or more surgical resections) of a surgically resectable tumor.
  • the disclosed methods of producing an expanded TIL population comprise obtaining one or more biopsies from the subject (such as, for example, percutaneous tumor samples).
  • biopsy can include any partial removal of a tissue such as excisional, incisional, core, or fine needle aspiration biopsies.
  • TILs obtained from biopsies such as, for example, core biopsies including core needle biopsies
  • core biopsies such as, for example core needle biopsies
  • core biopsies are used as the source of the tissue sample
  • core biopsies such as, for example core needle biopsies
  • core biopsies can be obtained using any device with which a core biopsy can be obtained (see, for example, the Bard Core Biopsy Instruments and Temno Biopsy Systems by Carefusion such as, BARD MAGNUM®, BARD MAX-CORE®, BARD BIOPTY-CUT®, BARD MARQUEE®, BARD MISSION®, and BARD MONOPTY® from CR Bard, Inc.).
  • the needle for obtaining the biopsy can be 6, 8, 10, 12, 14, 16, 18, or 20 gauge needle with a needle length between about 2cm and to about 30cm long, preferably between about 10cm and about 25 cm long, more preferably between about 16cm and about 20cm long.
  • the needle length for obtaining a core biopsy can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30cm long.
  • the penetration depth of the needle can be between about 15mm and 30mm, preferably between about 20mm and 25 mm.
  • the penetration depth can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30mm.
  • the use of core biopsy allows the ability to target certain and possibly multiple areas of a tumor.
  • methods of increasing the proportion of Stem-like CD8 T cells in a population of TILs further comprising the use of imaging techniques such as radiomics to guide TIL acquisition.
  • tissue samples including, but not limited to biopsies (such as, for example, core biopsies including core needle biopsies) and/or surgical resections provide the added advantage of not requiring further sectioning (i.e., making fragments), but can be directly digested.
  • the disclosed methods can comprise placing the tissue sample directly into a digesting solution (such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®)).
  • a digesting solution such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®)).
  • a digesting solution such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting
  • the one or more core biopsies are digested directly from the patient without disaggregation of the specimen.
  • Digests are well known in the art and typically comprise a collagenase, hyaluronidase, and DNAse. It is understood and herein contemplated that the digest can comprise at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®).
  • collagenase e.g., XIAFLEX®
  • hyaluronidase e.g., HYLENEX®
  • DNAse e.g., PULMOZYME®
  • the digest can occur directly from the tissue sample without prior fragmentation (mechanical or otherwise) or the separation or pooling of fragments thereby creating a bulk non-purified digest.
  • concentration of fragmented and/or digested cells used in the pre-REP of the disclosed methods can affect the yield and or efficacy of the disclosed methods.
  • the methods utilizes less than 5x10 6 cells, for example, the method can use 4x10 6 , 3x10 6 , 2x10 6 , 1x10 6 , 9x10 5 , 8x10 5 , 7x10 5 , 6x10 5 , 5x10 5 , 4x10 5 , 3x10 5 , 2x10 5 , or 1x10 5 or less bulk non-purified digest cells per tissue culture well.
  • Also disclosed herein are methods of increasing the proportion of Stem-like CD8 T cells in a population of TILs, further adding autologous B cells to the culture of TILs and CD40L.
  • the methods can further comprise the use of IL-2 in the culture. It is understood and herein contemplated that the concentration of the IL-2 can be adjusted to maximize the expansion of TILs.
  • the IL-2 concentration used to culture TILs can be 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000 IU/mL or more.
  • the culture process employed by the art understood methods takes 5-7 weeks to expand TILs from bulk non-purified tumor digests.
  • TILs This is a significant problem in the art as additional time to initiating adoptive transfer therapy of TILs represents an increased risk to the patient due to progression of malignancy while the cell product is being prepared.
  • the added time needed for culturing requires additional resources of the hospital in additional personnel to requirements to maintain the culture and costs for media and maintaining a cleanroom.
  • the present method decreases the expansion time to less than 5 weeks resulting in decreased attrition patients from therapy secondary to disease progression.
  • culturing to obtain an expanded population of TILs can occur for any time between 1 day and 5 weeks (35 days), preferably between 21 days (3 weeks) and 5 weeks (35 days), more preferably between 4 weeks (28 days) and 5 weeks (35 days).
  • the culture time can be less than 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days.
  • the pre-REP expansion is harvested when the desired expansion is reached, but not more than 4 weeks.
  • TIL expansion methods wherein the pre-REP culture is 1, 2, 3, 4, 5, 6, 7 (1 week) ,8, 9, 10, 11, 12, 13, 14 (2 weeks), 15, 16, 17, 18, 19, 20, 21 (3 weeks), 22, 23, 24, 25, 26, 27, or 28 (4 weeks) days.
  • the REP can occur for 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days between 1 and 3 days, between 3 and 5 days, between 3 and 7 days, between 3 and 11 days, between 3 and 14 days, between 5 and 7 days, between 5 and 11 days, between 5 and 14 days, between 7 and 11 days, between 7 and 14 days, at least 7 days, at least 11 days, or at least 14 days.
  • the pre-REP TIL can be frozen and used at a later time.
  • the fresh or thawed pre-REP TIL are submitted to a rapid expansion protocol (REP) can occur for 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days between 1 and 3 days, between 3 and 5 days, between 3 and 7 days, between 3 and 11 days, between 3 and 14 days, between 5 and 7 days, between 5 and 11 days, between 5 and 14 days, between 7 and 11 days, between 7 and 14 days, at least 7 days, at least 11 days, or at least 14 days.
  • the Attorney Docket No: 10110-366WO1 TILs can be thawed for 1-3 days.
  • a second culture of thawed TILs can be used to augment the number of TILs.
  • the exchange of media can comprise 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% removal and replacement of media. This media exchange can be accomplished employing any acceptable method for proper tissue culture maintenance known in the art.
  • the media exchange can occur at least one time during the culture of the TILs.
  • the media in the reservoir can be exchanged 1, 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 times during the culture period. That is, the media exchange can occur once during the culture period, once every 15 days, once every 10 days, once every 7 days, once every 5 days, once every other day, or about 2 to 3 times per week.
  • the culture methods employed herein can utilize any complete media comprising IL-2 appropriate for the growth and propagation of the TILs, including, but not limited to Minimum Essential Medium (MEM), Eagles’s Minimum Essential Medium (EMEM), Dulbecco’s Minimum Essential Medium (DMEM) Medium 199, RPMI 1640, CMRL-1066, BGJb Medium, Iscove’s Modified Dulbecco’s Medium (IMDM), and Blood Cell Media.
  • MEM Minimum Essential Medium
  • EMEM Minimum Essential Medium
  • DMEM Minimum Essential Medium
  • RPMI 1640 RPMI 1640
  • CMRL-1066 CMRL-1066
  • BGJb Medium Iscove’s Modified Dulbecco’s Medium
  • IMDM Blood Cell Media.
  • the TILs can be cultured in any gas permeable reservoir suitable for cell culture and the expansion of TILs. In one aspect, it is understood and herein contemplated that large tissue culture flasks can slow down the expansion of TILs as it takes longer
  • the gas permeable reservoir can be a tissue culture plate comprising 6 (approximately 10cm 2 surface area per well and 60cm 2 total surface area), 12(approximately 4cm 2 surface area per well and approximately 48cm 2 total surface area), 24 (approximately 2cm 2 surface area per well and approximately 48cm 2 total surface area), 48(approximately 1cm 2 surface area per well and approximately 48cm 2 total surface area), or 96 (approximately 0.32cm 2 surface area per well and 31cm 2 total surface area) wells (for example, G-Rex24 well plate or G-Rex6 well plate manufactured by Wilson Wolf).
  • the plates can be silicone coated.
  • CP-870,893 (now licensed to Roche Diagnostics under the names RO7009789 or Selicrelumab) is a fully humanized monoclonal IgG2 antibody that binds CD40 with a very high affinity (Kd of 0.4 nmol/l) (66,67).
  • CP-870,893 has been shown in preclinical studies to be a strong agonist of CD40 without eliciting antibody-dependent cellmediated cytotoxicity (ADCC), a mechanism through which an antibody induces target lysis by activating host leukocytic effector cells, or complement dependent cytotoxicity, a cascade of complement- related reactions leading to target lysis.
  • ADCC antibody-dependent cellmediated cytotoxicity
  • a study was conducted in 22 patients who had chemotherapy-naive advanced pancreatic ductal adenocarcinoma (PDA). The combination of a 0.2 mg/kg dose of CP- 870,893 every 3 weeks and standard-of-care gemcitabine was well tolerated in the subjects.
  • Dacetuzumab also named SEA-40 or SGN-40, is a humanized CD40 targeted IgG1 mAb developed by Seattle Genetics, Inc. As a weak agonist (Kd ⁇ 1 nmol/l), dacetuzumab does not block the CD40/CD40L interaction in vitro. Dacetuzumab was engineered in an afucosylated IgG1 format to improve the ADCC potential.
  • dacetuzumab induces apoptosis of non-Hodgkin's lymphoma cells in vivo by ADCC, antibody-dependent cellular phagocytosis (ADCP), and direct apoptotic signaling.
  • ADCC antibody-dependent cellular phagocytosis
  • apoptotic signaling apoptotic signaling.
  • ChiLob 7/4 (University of Southampton, UK) is a chimeric agonistic anti-CD40 IgG1 antibody. Preclinical studies showed that ChiLob 7/4 has the ability to inhibit the growth of various CD40-expressing human malignant lymphoma and epithelial cell lines.
  • CDX-1140 developed by Celldex Therapeutics, Inc., is a human IgG2 antibody that stimulates CD40 signalling without the requirement for cross-linking or Fc receptor interactions.
  • ABBV-927 (AbbVie, Inc.) is an anti-CD40/anti-mesothelin bispecific antibody that is being tested in phase I trials for the treatment of advanced solid tumours, including non- small cell lung cancer, squamous cell carcinoma of the head and neck, cutaneous malignant melanoma, and pancreatic adenocarcinoma, as monotherapy or in combination with other immunotherapies (anti-PD-1 and anti-OX40 antibodies).
  • APX005M developed by Apexigen, is a humanized mAb IgG1/k against CD40.
  • Patent No.8,088,383 describes methods for treating B-cell malignancies using antagonist anti-CD40 antibodies, which is incorporated herein for the teaching of these antibodies and methods.
  • the monoclonal antibody 15B8 represents a suitable antagonist anti-CD40 antibody for use in the methods of the present invention. This antibody is described in U.S. Provisional Application Ser. No.60/237,556, titled “Human Anti-CD40 Antibodies,” filed Oct.2, 2000, and PCT International Application No.
  • the 15B8 antibody is a fully human anti-CD40 monoclonal antibody of the IgG2 isotype produced from the hybridoma cell line 15B8.
  • the cell line was created using splenocytes from an immunized xenotypic mouse containing a human immunoglobulin locus (Abgenix). The spleen cells were fused with the mouse myeloma SP2/0 cells (Sierra BioSource).
  • the resulting hybridomas were sub-cloned several times to create the stable monoclonal cell line 15B8.
  • the hybridoma cell line 15B8 was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Attorney Docket No: 10110-366WO1 Manassas, Va., USA, on Oct.25, 2001, under the terms of the Budapest Treaty and assigned Patent Deposit— Designation PTA-3814.
  • the 15B8 cell line was adapted to grow in protein-free medium and used to create a Master Cell Bank. The Master Cell Bank was tested for identity and adventitious and endogenous contaminants. The Master Cell Bank was used to manufacture the desired human IgG2.
  • the respective 15B8 antibody was purified using chromatography and filtration procedures.
  • the anti-CD40 antibody 15B8 is a polypeptide composed of 1,284 amino acid residues with a predicted molecular weight of 149,755 with two heavy chains and two light chains in a heterodimeric arrangement. Amino acid analysis reveals that the antibody is composed of equimolar amounts of heavy and light chains.
  • the nucleotide and amino acid sequences for the variable region for the light chain are set forth in SEQ ID NO:1 and SEQ ID NO: 2, respectively.
  • the nucleotide and amino acid sequences for the variable region for the heavy chain are set forth in SEQ ID NO: 3 and SEQ ID NO: 4, respectively.
  • the 15B8 monoclonal antibody binds soluble CD40 in ELISA-type assays.
  • 15B8 When tested in vitro for effects on proliferation of B cells from numerous primates, 15B8 acts as an agonistic anti- CD40 antibody in cynomologus, baboon, and rhesus monkeys. In assays with humans, chimpanzees, and marmosets, 15B8 is an antagonist anti-CD40 antibody. The binding affinity of 15B8 to human CD40 is 3.1 ⁇ 10 ⁇ 9 M as determined by the BiacoreTM assay. [0107] Suitable antagonist anti-CD40 antibodies for use in the methods of the present invention exhibit a strong single-site binding affinity for the CD40 cell-surface antigen.
  • the monoclonal antibodies of the invention exhibit a dissociation constant (Kd) for CD40 of at least 10 ⁇ 5 M, at least 3 ⁇ 10 ⁇ 5 M, preferably at least 10 ⁇ 6 M to 10 ⁇ 7 M, more preferably at least 10 ⁇ 8 M to about 10 ⁇ 20 M, yet more preferably at least 5 ⁇ 10 ⁇ 9 M to about 10 ⁇ 18 M, most preferably at least about 5 ⁇ 10 ⁇ 9 M to about 10 ⁇ 16 M, such as 10 ⁇ 8 M, 5 ⁇ 10 ⁇ 9 M, 10 ⁇ 9 M, 5 ⁇ 10 ⁇ 10 M, 10 ⁇ 10 M, 5 ⁇ 10 ⁇ 11 M, 10 ⁇ 11 M, 5 ⁇ 10 ⁇ 12 M, 10 ⁇ 12 M, 5 ⁇ 10 ⁇ 13 M, 10 ⁇ 13 M, 5 ⁇ 10 ⁇ 14 M, 10 ⁇ 14 M, 5 ⁇ 10 ⁇ 15 M, 10 ⁇ 15 M, 5 ⁇ 10 ⁇ 16 M, or 10 ⁇ 16 M, as measured using a standard assay such as BiacoreTM.
  • Antibodies are used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term “antibodies” are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules or fragments thereof, as long as they are chosen for their ability to interact with CD40 such that CD40 is inhibited from interacting with CD40L.
  • the antibodies can be tested for their desired activity using the in vitro assays described herein, or by analogous methods, after which their in vivo therapeutic and/or prophylactic activities are tested according to known clinical testing methods.
  • IgA immunoglobulins
  • IgD immunoglobulins
  • IgE immunoglobulins
  • IgG immunoglobulins
  • IgG immunoglobulins
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.
  • the term “monoclonal antibody” as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity.
  • the disclosed monoclonal antibodies can be made using any procedure which produces mono clonal antibodies.
  • disclosed monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975).
  • a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
  • the lymphocytes may be immunized in vitro.
  • the monoclonal antibodies may also be made by recombinant DNA methods. DNA encoding the disclosed monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, e.g., as described in U.S. Patent No.5,804,440 to Burton et al. and U.S. Patent No.6,096,441 to Barbas et al. [0113]
  • In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec.22, 1994 and U.S. Pat. No.4,342,566.
  • antibody or fragments thereof encompasses chimeric antibodies and hybrid antibodies, with dual or multiple antigen or epitope specificities, and fragments, such as F(ab’)2, Fab’, Fab, Fv, scFv, VHH, and the like, including hybrid fragments.
  • fragments of the antibodies that retain the ability to bind their specific antigens are provided.
  • antibody or fragment thereof fragments of antibodies which maintain CD40 binding activity are included within the meaning of the term “antibody or fragment thereof.”
  • Such antibodies and fragments can be made by techniques known in the art and can be screened for specificity and activity according to the methods set forth in the Examples and in general methods for producing antibodies and screening antibodies for specificity and activity (See Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).
  • conjugates of antibody fragments and antigen binding proteins single chain antibodies.
  • the fragments can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the antibody or antibody fragment is not significantly altered or impaired compared to the non-modified antibody or antibody Attorney Docket No: 10110-366WO1 fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody or antibody fragment must possess a bioactive property, such as specific binding to its cognate antigen.
  • Functional or active regions of the antibody or antibody fragment may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment. (Zoller, M.J. Curr. Opin. Biotechnol.3:348-354, 1992).
  • Fragments of the anti-CD40 antibodies are suitable for use in the methods of the invention so long as they retain the desired affinity of the full-length antibody. Thus, a fragment of an anti-CD40 antibody will retain the ability to bind to the CD40 B-cell surface antigen.
  • Such fragments are characterized by properties similar to the corresponding full- length antagonist anti-CD40 antibody, that is the fragments will 1) specifically bind a human CD40 antigen expressed on the surface of a human cell; 2) are free of significant agonist activity when bound to a CD40 antigen on a normal human B cell; and 3) exhibit antagonist activity when bound to a CD40 antigen on a malignant human B cell.
  • the full-length antagonist anti-CD40 antibody exhibits antagonist activity when bound to the CD40 antigen on the surface of a normal human B cell
  • the fragment will also exhibit such antagonist activity.
  • Such fragments are referred to herein as “antigen-binding” fragments.
  • an antibody can also refer to a human antibody and/or a humanized antibody.
  • Many non-human antibodies e.g., those derived from mice, rats, or rabbits
  • are naturally antigenic in humans and thus can give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response.
  • an antibody (or fragment thereof) may be conjugated to a therapeutic moiety such as a cytotoxin, a therapeutic agent, or a radioactive metal ion.
  • a cytotoxin or cytotoxic agent includes any agent that is detrimental to cells.
  • Examples include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.
  • Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6- mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)
  • antimetabolites e.g.,
  • the conjugates of the invention can be used for modifying a given biological response; the drug moiety is not to be construed as limited to classical chemical therapeutic agents.
  • the drug moiety may be a protein or polypeptide possessing a desired biological activity.
  • proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, interferon-alpha, interferon-beta, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2 (“IL-2”), interleukin-6 (“IL-6”), granulocyte macrophase colony stimulating factor (“GM-CSF”), granulocyte colony stimulating factor (“G-CSF”), or other growth factors.
  • IL-1 interleukin-1
  • IL-2 interleukin-2
  • anti-CD40 antibody encompasses chimeric anti-CD40 antibodies.
  • chimeric antibodies is intended antibodies that are most preferably derived using recombinant deoxyribonucleic acid techniques and which comprise both human (including immunologically “related” species, e.g., chimpanzee) and non-human components.
  • the constant region of the chimeric antibody is most preferably substantially identical to the constant region of a natural human antibody; the variable region of the chimeric antibody is most preferably derived from a non-human source and has the desired antigenic specificity to the CD40 cell-surface antigen.
  • the non-human source can be any vertebrate source that can be used to generate antibodies to a human CD40 cell-surface antigen or material comprising a human CD40 cell-surface antigen.
  • Such non-human sources include, but are not limited to, rodents (e.g., rabbit, rat, mouse, etc.; see, for example, U.S. Pat. No.4,816,567, herein incorporated by reference) and non-human primates (e.g., Old World Monkey, Ape, etc.; see, for example, U.S. Pat. Nos.5,750,105 and 5,756,096; herein incorporated by reference).
  • the phrase “immunologically active” when used in reference to chimeric anti-CD40 antibodies means a chimeric antibody that binds human CD40.
  • Attorney Docket No: 10110-366WO1 b) Human antibodies [0121]
  • the disclosed human antibodies can be prepared using any technique.
  • the disclosed human antibodies can also be obtained from transgenic animals. For example, transgenic, mutant mice that are capable of producing a full repertoire of human antibodies, in response to immunization, have been described (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci.
  • Humanized anti-CD40 antibodies are also encompassed by the term anti-CD40 antibody as used herein.
  • humanized is intended forms of anti-CD40 antibodies that contain minimal sequence derived from non-human immunoglobulin sequences.
  • Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule.
  • a humanized form of a non-human antibody is a chimeric antibody or antibody chain (or a fragment thereof, such as an sFv, Fv, Fab, Fab’, F(ab’)2, or other antigen-binding portion of an antibody) which contains a portion of an antigen binding site from a non-human (donor) antibody integrated into the framework of a human (recipient) antibody.
  • a humanized antibody residues from one or more complementarity determining regions (CDRs) of a recipient (human) antibody molecule are replaced by residues from one or more CDRs of a donor (non-human) antibody molecule that is known to have desired antigen binding characteristics (e.g., a certain level of specificity and affinity for the target antigen).
  • CDRs complementarity determining regions
  • donor non-human antibody molecule
  • Fv framework (FR) residues of the human antibody are replaced by corresponding non-human residues.
  • Humanized antibodies may also contain residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences.
  • a humanized antibody has one or more amino acid residues Attorney Docket No: 10110-366WO1 introduced into it from a source which is non-human.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • Humanized antibodies generally contain at least a portion of an antibody constant region (Fc), typically that of a human antibody (Jones et al., Nature, 321:522-525 (1986), Reichmann et al., Nature, 332:323-327 (1988), and Presta, Curr. Opin. Struct. Biol., 2:593-596 (1992)).
  • Fc antibody constant region
  • humanized antibodies can be generated according to the methods of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986), Riechmann et al., Nature, 332:323-327 (1988), Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • Methods that can be used to produce humanized antibodies are also described in U.S. Patent No.4,816,567 (Cabilly et al.), U.S. Patent No.5,565,332 (Hoogenboom et al.), U.S.
  • the broadly neutralizing anti-CD40 antibodies and antibody fragments can also be administered to patients or subjects as a nucleic acid preparation (e.g., DNA or RNA) that encodes the antibody or antibody fragment, such that the patient's or subject's own cells take up the nucleic acid and produce and secrete the encoded antibody or antibody fragment.
  • a nucleic acid preparation e.g., DNA or RNA
  • the delivery of the nucleic acid can be by any means, as disclosed herein, for example.
  • Antagonist anti-CD40 antibodies useful in the methods of the present invention include the 15B8 monoclonal antibody disclosed herein as well as antibodies differing from this antibody but retaining the CDRs; and antibodies with one or more amino acid addition(s), deletion(s), or substitution(s), wherein the antagonist activity is measured by inhibition of malignant B cell proliferation and/or differentiation.
  • the invention also encompasses de-immunized antagonist anti-CD40 antibodies, which can be produced as described in, for example, International Publication Nos. WO 98/52976 and WO 0034317; herein incorporated by reference.
  • fusion proteins comprising an antagonist anti-CD40 antibody of the invention, or a fragment thereof, which fusion proteins can be synthesized or expressed from corresponding polynucleotide vectors, as is known in the art. Such fusion proteins are described with reference to conjugation of antibodies as noted below.
  • the antibodies of the present invention can have sequence variations produced using methods described in, for example, Patent Publication Nos.
  • EP 0983303 A1, WO 00/34317, and WO 98/52976 incorporated herein by reference.
  • sequences within the CDR can cause an antibody to bind to MHC Class II and trigger an unwanted helper T cell response.
  • a conservative substitution can allow the antibody to retain binding activity yet lose its ability to trigger an unwanted T cell response. Any such conservative or non-conservative substitutions can be made using art-recognized methods, such as those noted elsewhere herein, and the resulting antibodies will fall within the scope of the invention.
  • the variant antibodies can be routinely tested for antagonist activity, affinity, and specificity using methods described herein. G.
  • Chemokine gene signature [0128] Disclosed herein is a method for predicting the responsiveness of a subject to CD40 agonist therapy, such as agonist anti-CD40 therapy, comprising assaying a tumor sample from the subject for a 12 Chemokine gene signature demonstrating that the tumor comprises tertiary lymphoid structures containing B cells.
  • Chemokines which are small protein molecules involved in immune and inflammatory responses, direct leukocyte trafficking to areas of injury as well as to locations where primary immune responses are initiated (secondary lymphoid tissues such as lymph nodes, spleen, Peyer's patches, and tonsils).
  • chemokine molecules There are presently four classes of chemokine molecules (C, CC, CXC, and CX3C) that are named for the number and location of cysteine residues on the amino terminus of the protein. These molecules communicate with their target cells via G-protein coupled receptors that are pertussis toxin sensitive. Different chemokines act on different leukocyte populations, thereby modulating the influx of immune effector cells to the area in question based on the needs of the particular situation. Chemokines are Attorney Docket No: 10110-366WO1 secreted proteins involved in immunoregulatory and inflammatory processes. The chemokines of the disclosed gene signature are shown in Table 1. Table 1: Chemokines Gene Gene Name GenBank Acc. No: GenBank Acc.
  • the methods include assaying the presence or levels of chemokine mRNA or proteins in the sample.
  • the presence and/or level of a protein can be evaluated using methods known in the art, e.g., using quantitative immunoassay methods.
  • the presence and/or level of an mRNA can be evaluated using methods known in the art, e.g., Northern blotting or quantitative PCR methods, e.g., RT-PCR.
  • high throughput methods e.g., protein or gene chips as are known in the art (see, e.g., Ch.12, Genomics, in Griffiths et al., Eds. Modern genetic Analysis, 1999, W. H.
  • the methods include assaying levels of one or more control genes or proteins, and comparing the level of expression of the chemokine genes or proteins to the level of the control genes or proteins, to normalize the levels of the chemokine genes or proteins.
  • Suitable endogenous control genes includes a gene whose expression level should not differ between samples, such as a housekeeping or maintenance gene, e.g., 18S ribosomal RNA; beta Actin; Glyceraldehyde-3-phosphate dehydrogenase; Phosphoglycerate kinase 1; Peptidylprolyl isomerase A (cyclophilin A); Ribosomal protein L13a; large Ribosomal protein P0; Beta-2-microglobulin; Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; Succinate dehydrogenase; Transferrin receptor (p90, CD71); Aminolevulinate, delta-, synthase 1; Glucuronidase, beta; Hydroxymethyl-bilane synthase; Hypoxanthine phosphoribosyltransferase 1; TATA box binding protein; and/or Tub
  • the methods described herein can be performed on cells from a tumor.
  • the cells can be obtained by known methods, e.g., during a biopsy (such as a core needle biopsy), or during a surgical procedure to remove all or part of the tumor.
  • the cells can be used fresh, frozen, fixed, and/or preserved, so long as the mRNA or protein that is to be assayed is maintained in a sufficiently intact state to allow accurate analysis.
  • the levels of the chemokine genes in the tumor sample can be compared individually to levels in a reference.
  • the reference levels can represent levels in a tumor that does not have tertiary lymphoid structures (TLSs).
  • TLSs tertiary lymphoid structures
  • reference levels can represent levels in a tumor that does shave TLSs. In some embodiments, the reference levels represent a threshold. [0134] In some embodiments of the methods described herein, values representing the levels of the chemokine genes can be summed to produce a “chemokine gene score” that can be compared to a reference chemokine gene score, wherein a chemokine gene score that is above the reference chemokine gene score indicates that the tumor will produce TILs with enhanced tumor reactivity, and an chemokine gene score below the reference score indicates that the tumor will produce TILs that do not have enhanced tumor reactivity.
  • the expression levels of each of the evaluated genes can be assigned a value (e.g., a value that represents the expression level of the gene, e.g., normalized to an endogenous control gene as described herein). That value (optionally weighted to increase or decrease its effect on the final score) can be summed to produce an Attorney Docket No: 10110-366WO1 immune-related gene score.
  • a value e.g., a value that represents the expression level of the gene, e.g., normalized to an endogenous control gene as described herein. That value (optionally weighted to increase or decrease its effect on the final score) can be summed to produce an Attorney Docket No: 10110-366WO1 immune-related gene score.
  • the methods described herein can include determining levels (or scores) for all of the 12 chemokines. In some embodiments all of the genes are evaluated, but in some embodiments a subset of one or all of the sets is evaluated. H.
  • TILs tumor infiltrating lymphocytes
  • methods of treating, decreasing, inhibiting, reducing, ameliorating and/or preventing a cancer and/or metastasis in a subject comprising administering to the subject the expanded TILs disclosed herein.
  • methods of treating, decreasing, inhibiting, reducing, ameliorating and/or preventing a cancer and/or metastasis in a subject comprising administering to the subject comprising obtaining tumor infiltrating lymphocytes (TILs) from the subject; culturing the TILs in media comprising one or more of the isolated CD40L monomers comprising a L259F substitution (including, but not limited to isolated CD40L monomers further comprising a substitution at residue 133 (K133T), residue 139 (Q139H or Q139K)), residue 185 (S185G), residue 217 (P217H or P217R)), residue 240 (N240K), and/or residue 274 (E274K) such as, for example, the isolated CD40
  • chemokine (C-C motif) ligand 2 CCL2
  • CCL3 CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18)
  • CCL19 CCL21
  • chemokine (C-X-C motif) ligand 9 CXCL9
  • CXCL10 CXCL11, and CXCL13 in tumor cells
  • comparing the tumor gene expression levels to reference gene expression levels and identifying a subject who has tumor gene expression levels above the reference gene expression levels.
  • the TILs are obtained from a biopsy (such as, for example, core biopsies and/or one or more surgical resections) of a surgically resectable tumor.
  • the disclosed methods of producing an expanded TIL population comprise obtaining one or more biopsies from the subject (such as, for example, percutaneous tumor samples).
  • biopsy can include any partial removal of a tissue such as excisional, incisional, core, or fine needle aspiration biopsies.
  • TILs obtained from biopsies such as, for example, core biopsies including core needle biopsies
  • core biopsies such as, for example core needle biopsies
  • core biopsies are used as the source of the tissue sample
  • core biopsies such as, for example core needle biopsies
  • core biopsies can be obtained using any device with which a core biopsy can be obtained (see, for example, the Bard Core Biopsy Instruments and Temno Biopsy Systems by Carefusion such as, BARD MAGNUM®, BARD MAX-CORE®, BARD BIOPTY-CUT®, BARD MARQUEE®, BARD MISSION®, and BARD MONOPTY® from CR Bard, Inc.).
  • the needle for obtaining the biopsy can be 6, 8, 10, 12, 14, 16, 18, or 20 gauge needle with a needle length between about 2cm and to about 30cm long, preferably between about 10cm and about 25 cm long, more preferably between about 16cm and about 20cm long.
  • the needle length for obtaining a core biopsy can be 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30cm long.
  • the penetration depth of the needle can be between about 15mm and 30mm, preferably between about 20mm and 25 mm.
  • the penetration depth can be 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30mm.
  • the use of core biopsy allows the ability to target certain and possibly multiple areas of a tumor.
  • methods of treating, inhibiting, reducing, decreasing, ameliorating, and/or preventing a cancer and/or metastasis further comprising the use of imaging techniques such as radiomics to guide TIL acquisition.
  • tissue samples including, but not limited to biopsies (such as, for example, core biopsies including core needle biopsies) and/or surgical resections provide the added advantage of not requiring further sectioning (i.e., making fragments), but can be directly digested.
  • the disclosed methods can comprise placing the tissue Attorney Docket No: 10110-366WO1 sample directly into a digesting solution (such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®)).
  • a digesting solution such as, for example a at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®)).
  • a digesting solution such as, for example a at least one, or a combination of two, or all three of the
  • TILs tumor infiltrating lymphocytes
  • the one or more core biopsies are digested directly from the patient without disaggregation of the specimen.
  • Digests are well known in the art and typically comprise a collagenase, hyaluronidase, and DNAse. It is understood and herein contemplated that the digest can comprise at least one, or a combination of two, or all three of the human or humanized enzymes selected from the group consisting of collagenase (e.g., XIAFLEX®), hyaluronidase (e.g., HYLENEX®), and DNAse (e.g., PULMOZYME®).
  • collagenase e.g., XIAFLEX®
  • hyaluronidase e.g., HYLENEX®
  • DNAse e.g., PULMOZYME®
  • the digest can occur directly from the tissue sample without prior fragmentation (mechanical or otherwise) or the separation or pooling of fragments thereby creating a bulk non-purified digest.
  • concentration of fragmented and/or digested cells used in the pre-REP of the disclosed methods can affect the yield and or efficacy of the disclosed methods.
  • the methods utilizes less than 5x10 6 cells, for example, the method can use 4x10 6 , 3x10 6 , 2x10 6 , 1x10 6 , 9x10 5 , 8x10 5 , 7x10 5 , 6x10 5 , 5x10 5 , 4x10 5 , 3x10 5 , 2x10 5 , or 1x10 5 or less bulk non-purified digest cells per tissue culture well.
  • the methods can further comprise the use of IL-2 in the culture. It is understood and herein contemplated that the concentration of the IL-2 can be adjusted to maximize the expansion of TILs.
  • the IL-2 concentration used to culture TILs can be 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000 IU/mL or more.
  • the culture process employed by the art understood methods takes 5-7 weeks to expand TILs from bulk non-purified tumor digests. This is a significant problem in the art as additional time to initiating adoptive transfer therapy of TILs represents an increased risk to the patient due to progression of malignancy while the cell product is being prepared. Moreover, the added time needed for culturing requires additional resources of the hospital in additional personnel to requirements to maintain the culture and costs for media and maintaining a cleanroom.
  • the present method decreases the expansion time to less than 5 Attorney Docket No: 10110-366WO1 weeks resulting in decreased attrition patients from therapy secondary to disease progression.
  • culturing to obtain an expanded population of TILs can occur for any time between 1 day and 5 weeks (35 days), preferably between 21 days (3 weeks) and 5 weeks (35 days), more preferably between 4 weeks (28 days) and 5 weeks (35 days).
  • the culture time can be less than 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days.
  • the pre-REP expansion is harvested when the desired expansion is reached, but not more than 4 weeks.
  • TIL expansion methods wherein the pre-REP culture is 1, 2, 3, 4, 5, 6, 7 (1 week), 8, 9, 10, 11, 12, 13, 14 (2 weeks), 15, 16, 17, 18, 19, 20, 21 (3 weeks), 22, 23, 24, 25, 26, 27, or 28 (4 weeks) days.
  • the REP can occur for 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days between 1 and 3 days, between 3 and 5 days, between 3 and 7 days, between 3 and 11 days, between 3 and 14 days, between 5 and 7 days, between 5 and 11 days, between 5 and 14 days, between 7 and 11 days, between 7 and 14 days, at least 7 days, at least 11 days, or at least 14 days.
  • the pre-REP TIL can be frozen and used at a later time.
  • the fresh or thawed pre-REP TIL are submitted to a rapid expansion protocol (REP) which can last less than 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days.
  • REP rapid expansion protocol
  • the REP can occur for 1, 2, 3, 4, 5, 6, 7 ,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days between 1 and 3 days, between 3 and 5 days, between 3 and 7 days, between 3 and 11 days, between 3 and 14 days, between 5 and 7 days, between 5 and 11 days, between 5 and 14 days, between 7 and 11 days, between 7 and 14 days, at least 7 days, at least 11 days, or at least 14 days.
  • frozen TILs are used, the TILs can be thawed for 1-3 days.
  • a second culture of thawed TILs can be used to augment the number of TILs.
  • the exchange of media can comprise 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% removal and replacement of media. This media exchange can be accomplished employing any acceptable method for proper tissue culture maintenance known in the art.
  • the media exchange can occur at least one time during the culture of the TILs.
  • the media in the reservoir can be exchanged 1, Attorney Docket No: 10110-366WO1 2, 3, 4, 5, 6, 7, 8, 9 ,10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 times during the culture period. That is, the media exchange can occur once during the culture period, once every 15 days, once every 10 days, once every 7 days, once every 5 days, once every other day, or about 2 to 3 times per week.
  • the culture methods employed herein can utilize any complete media comprising IL-2 appropriate for the growth and propagation of the TILs, including, but not limited to Minimum Essential Medium (MEM), Eagles’s Minimum Essential Medium (EMEM), Dulbecco’s Minimum Essential Medium (DMEM) Medium 199, RPMI 1640, CMRL-1066, BGJb Medium, Iscove’s Modified Dulbecco’s Medium (IMDM), and Blood Cell Media.
  • MEM Minimum Essential Medium
  • EMEM Minimum Essential Medium
  • DMEM Minimum Essential Medium
  • RPMI 1640 RPMI 1640
  • CMRL-1066 CMRL-1066
  • BGJb Medium Iscove’s Modified Dulbecco’s Medium
  • IMDM Blood Cell Media.
  • the TILs can be cultured in any gas permeable reservoir suitable for cell culture and the expansion of TILs. In one aspect, it is understood and herein contemplated that large tissue culture flasks can slow down the expansion of TILs as it takes longer
  • the gas permeable reservoir can be a tissue culture plate comprising 6 (approximately 10cm 2 surface area per well and 60cm 2 total surface area), 12(approximately 4cm 2 surface area per well and approximately 48cm 2 total surface area), 24 (approximately 2cm 2 surface area per well and approximately 48cm 2 total surface area), 48(approximately 1cm 2 surface area per well and approximately 48cm 2 total surface area), or 96 (approximately 0.32cm 2 surface area per well and 31cm 2 total surface area) wells (for example, G-Rex24 well plate or G-Rex6 well plate manufactured by Wilson Wolf).
  • the plates can be silicone coated.
  • methods of treating, inhibiting, reducing, decreasing, ameliorating, and/or preventing a cancer and/or metastasis further comprising measuring the tumor gene expression level of chemokine (C-C motif) ligand 2 (CCL2), CCL3, CCL4, CCL5, CCL8, chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) (CCL18), CCL19, CCL21, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, and CXCL13 in tumor cells and comparing the tumor gene expression levels to reference gene expression levels; and identifying a subject who has tumor gene expression levels above the reference gene expression levels.
  • Tumors include malignancies of the various organ systems, such as affecting lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumors, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
  • the cancer is a melanoma, breast, lung, colorectal, urothelial, or genitourinary cancer.
  • carcinoma is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas.
  • the disease is renal carcinoma or melanoma.
  • Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
  • carcinosarcomas e.g., which include malignant tumors composed of carcinomatous and sarcomatous tissues.
  • the method comprises treating the patient with anti-CD40 antibodies or antigen binding fragments thereof.
  • the monoclonal antibodies have a strong affinity for CD40 and are characterized by a dissociation constant (Kd) of at least 10 ⁇ 5 M, preferably at least about 10 ⁇ 8 M to about 10 ⁇ 20 M, more preferably at least about 5 ⁇ 10 ⁇ 9 to about 10 ⁇ 16 M.
  • Suitable monoclonal antibodies have human constant regions; preferably they also have wholly or partially humanized framework regions; and most preferably are fully human antibodies or antigen-binding fragments thereof.
  • Examples of such monoclonal antibodies are the antibody designated herein as 15B8, the monoclonal antibody produced by the hybridoma cell line designated 15B8, a monoclonal antibody comprising an amino acid sequence selected from the group consisting of DIVMTQSPLSLSVAPGQPASISCKSSQSLLESYGETYLYWYLQKPGQPPQLLIYAVFK RFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQSMQLPLTFGGGTKVEIK Attorney Docket No: 10110-366WO1 (SEQ ID NO: 13) and QVQLQESGGGVVQPGRSLRLSCAASGFTFNNFGIHWVRQAPGKGLEWVAVISYDGS DKYYADSVKGRFTISRDNSKNTLNLQMNSLRAEDTAVYYCARDRRYYY
  • the disclosed anti-CD40 antibodies may be administered either alone, or as a pharmaceutical composition in combination with diluents and/or with other components such as IL-2, IL-15, or other cytokines or cell populations.
  • pharmaceutical compositions may comprise a target cell population as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
  • compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives.
  • buffers such as neutral buffered saline, phosphate buffered saline and the like
  • carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol
  • proteins polypeptides or amino acids
  • antioxidants e.g., antioxidants
  • chelating agents such as EDTA or glutathione
  • adjuvants e.g., aluminum hydroxide
  • preservatives e.g., aluminum hydroxide
  • an immunologically effective amount When “an immunologically effective amount”, “an anti-tumor effective amount”, “an tumor-inhibiting effective amount”, or “therapeutic amount” is indicated, the precise amount of the compositions of the present invention to be administered can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject).
  • the cells can be administered by using infusion techniques that are commonly known in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med.319:1676, 1988).
  • the therapy comprises administering to a patient a therapeutically effective dose of a pharmaceutical composition comprising suitable anti- CD40 antibodies or antigen-binding fragments thereof.
  • a therapeutically effective dose of the anti-CD40 antibody or fragment thereof is in the range from about 0.01 mg/kg to about 40 mg/kg, from about 0.01 mg/kg to about 30 mg/kg, from about 0.1 mg/kg to about 30 mg/kg, from about 1 mg/kg to about 30 mg/kg, from about 3 mg/kg to about 30 mg/kg, from about 3 mg/kg to about 25 mg/kg, from about 3 mg/kg to about 20 mg/kg, from about 5 mg/kg to about 15 mg/kg, or from about 7 mg/kg to about 12 mg/kg. It is recognized that the treatment may comprise administration of a single therapeutically effective dose or administration of multiple therapeutically effective doses of the anti-CD40 antibody or antigen-binding fragment thereof.
  • compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous (i.v.) injection, or intraperitoneally.
  • i.v. intravenous
  • the disclosed compositions are administered to a patient by intradermal or subcutaneous injection.
  • the disclosed compositions are administered by i.v. injection.
  • the compositions may also be injected directly into a tumor, lymph node, or site of infection.
  • the disclosed anti-CD40 antibodies are administered to a patient in conjunction with chemotherapy, therapeutic tumour vaccines, agitation of Toll-like receptors, cytokine therapy, and/or blockades of immune checkpoint inhibitors.
  • the disclosed anti-CD40 antibodies are administered to a patient in conjunction with carboplatin, cisplatin, etoposide, gemcitabine, ifosfamide, paclitaxel, and/or pemetrexed.
  • the disclosed anti-CD40 antibodies are administered to a patient in conjunction with atezolizumab, cabiralizumab, emactuzumab, nivolumab, pembrolizumab, rituximab, tremelimumab, and/or vanucizumab.
  • the disclosed anti-CD40 antibodies are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to thalidomide, dexamethasone, bortezomib, and lenalidomide.
  • the anti-CD40 antibodies may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation.
  • immunosuppressive agents such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies
  • other immunoablative agents such as CAM PATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and irradiation.
  • the TILs are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH.
  • chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH.
  • the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
  • the cancer of the disclosed methods can be any cell in a subject undergoing unregulated growth, invasion, or metastasis.
  • Cancers include prostate cancer, ovarian cancer, adenocarcinoma of the lung, breast cancer, endometrial cancer, gastric cancer, colon cancer, and pancreatic cancer.
  • the cancer comprises myelodysplastic syndrome, acute myeloid leukemia, or bi-phenotypic leukemia.
  • the cancer can be any neoplasm or tumor for which radiotherapy is currently used.
  • the cancer can be a neoplasm or tumor that is not sufficiently sensitive to radiotherapy using standard methods.
  • the cancer can be a sarcoma, lymphoma, leukemia, carcinoma, blastoma, or germ cell tumor.
  • a representative but non- Attorney Docket No: 10110-366WO1 limiting list of cancers that the disclosed compositions can be used to treat include lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin’s Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, kidney cancer, lung cancers such as small cell lung cancer and non-small cell lung cancer, neuroblastoma/glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, endometrial cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancers; testicular cancer; colon and
  • the disclosed anti-CD40 antibodies can be used in combination with any compound, moiety or group which has a cytotoxic or cytostatic effect.
  • Drug moieties include chemotherapeutic agents, which may function as microtubulin inhibitors, mitosis inhibitors, topoisomerase inhibitors, or DNA intercalators, and particularly those which are used for cancer therapy.
  • the disclosed treatments methods can also include the administration any anti- cancer therapy known in the art including, but not limited Abemaciclib, Abiraterone Acetate, ABITREXATE® (Methotrexate), ABRAXANE® (Paclitaxel Albumin-stabilized Nanoparticle Formulation), ABVD, ABVE, ABVE-PC, AC, AC-T, ADCETRIS® (Brentuximab Vedotin), ADE, Ado-Trastuzumab Emtansine, ADRIAMYCIN® (Doxorubicin Hydrochloride), Afatinib Dimaleate, AFINITOR® (Everolimus), AKYNZEO® (Netupitant and Palonosetron Hydrochloride), ALDARA® (Imiquimod), Aldesleukin, ALECENSA® (Alectinib), Alectinib, Alemtuzumab, ALIMTA® (Pemetrexed Disodium), ALIQ
  • the disclosed CD40L expanded TILs can be used in combination with a checkpoint inhibitor.
  • the two known inhibitory checkpoint pathways involve signaling through the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed-death 1 (PD-1) receptors.
  • CTLA-4 cytotoxic T-lymphocyte antigen-4
  • PD-1 programmed-death 1
  • CTL-4 cytotoxic T-lymphocyte antigen-4
  • PD-1 receptors are members of the CD28-B7 family of cosignaling molecules that play important roles throughout all stages of T cell function.
  • the PD-1 receptor also known as CD279 is expressed on the surface of activated T cells. Its ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273), are expressed on the surface of APCs such as dendritic cells or macrophages.
  • PD-L1 is the predominant ligand, while PD-L2 has a much more restricted expression pattern.
  • an inhibitory signal is transmitted into the T cell, which reduces cytokine production and suppresses T-cell proliferation.
  • Checkpoint inhibitors include, but are not limited to antibodies that block PD-1 (such as, for example, Nivolumab (BMS-936558 or MDX1106), pembrolizumab, cemiplimab , CT-011, MK-3475), PD-L1 (such as, for example, atezolizumab, avelumab, durvalumab, MDX-1105 (BMS-936559), MPDL3280A, or MSB0010718C), PD-L2 (such as, for example, rHIgM12B7), CTLA-4 (such as, for example, Ipilimumab (MDX-010), Tremelimumab (CP- 675,206)), IDO, B7-H3 (such as, for example, MGA271, MGD009, omburtamab), B7-H4, B7-H3, T cell immunoreceptor with Ig and ITIM domains (TIGIT)(such as, for example BMS-986207, O
  • the PDL1 inhibitor comprises an antibody that specifically binds PDL1, such as BMS-936559 (Bristol-Myers Squibb) or MPDL3280A (Roche).
  • the PD1 inhibitor comprises an antibody that specifically binds PD1, such as lambrolizumab (Merck), nivolumab (Bristol-Myers Squibb), or MEDI4736 (AstraZeneca).
  • Human monoclonal antibodies to PD-1 and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics are described in U.S. Patent No.8,008,449, which is incorporated by reference for these antibodies.
  • Anti-PD-L1 antibodies and uses therefor are described in U.S. Patent No.8,552,154, which is incorporated by reference for these antibodies.
  • Anticancer agent comprising anti-PD-1 antibody or anti-PD-L1 antibody are described in U.S. Patent No.8,617,546, which is incorporated by reference for these antibodies.
  • the disclosed CD40L expanded TILs can be used in combination with other cancer immunotherapies. There are two distinct types of immunotherapy: passive immunotherapy uses components of the immune system to direct targeted cytotoxic activity against cancer cells, without necessarily initiating an immune response in the patient, while active immunotherapy actively triggers an endogenous immune response. Passive strategies include the use of the monoclonal antibodies (mAbs) produced by B cells in response to a specific antigen.
  • mAbs monoclonal antibodies
  • mAbs have been the biggest success story for immunotherapy; the top three best-selling anticancer drugs in 2012 were mAbs.
  • rituximab (Rituxan, Genentech), which binds to the CD20 protein that is highly expressed on the surface of B cell malignancies such as non- Hodgkin’s lymphoma (NHL).
  • NHL non- Hodgkin’s lymphoma
  • CLL chronic lymphocytic leukemia
  • trastuzumab Herceptin; Genentech
  • HER2 human epidermal growth factor receptor 2
  • HER2 human epidermal growth factor receptor 2
  • co-stimulation can be provided through ligation of tumor necrosis Attorney Docket No: 10110-366WO1 factor receptor family members, including OX40 (CD134) and 4-1BB (CD137).
  • OX40 is of particular interest as treatment with an activating (agonist) anti-OX40 mAb augments T cell differentiation and cytolytic function leading to enhanced anti-tumor immunity against a variety of tumors.
  • such an additional therapeutic agent may be selected from an antimetabolite, such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine or cladribine.
  • an antimetabolite such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, decarbazine, hydroxyurea, asparaginase, gemcitabine or cladribine.
  • such an additional therapeutic agent may be selected from an alkylating agent, such as mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives, such as carboplatin.
  • an alkylating agent such as mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin and other platinum derivatives, such as carboplatin.
  • such an additional therapeutic agent may be selected from an anti-mitotic agent, such as taxanes, for instance docetaxel, and paclitaxel, and vinca alkaloids, for instance vindesine, vincristine, vinblastine, and vinorelbine.
  • an additional therapeutic agent may be selected from a topoisomerase inhibitor, such as topotecan or irinotecan, or a cytostatic drug, such as etoposide and teniposide.
  • a growth factor inhibitor such as an inhibitor of ErbBl (EGFR) (such as an EGFR antibody, e.g.
  • such an additional therapeutic agent may be selected from a tyrosine kinase inhibitor, such as imatinib (Glivec, Gleevec STI571) or lapatinib.
  • a disclosed antibody is used in combination with ofatumumab, zanolimumab, daratumumab, ranibizumab, nimotuzumab, panitumumab, hu806, daclizumab (Zenapax), basiliximab (Simulect), infliximab (Remicade), adalimumab (Humira), natalizumab (Tysabri), omalizumab (Xolair), efalizumab (Raptiva), and/or rituximab.
  • a therapeutic agent for use in combination with TILs for treating the disorders as described above may be an anti-cancer cytokine, chemokine, or combination thereof.
  • suitable cytokines and growth factors include IFN ⁇ , IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b, IL- 29, KGF, IFN ⁇ (e.g., INF ⁇ 2b), IFN , GM-CSF, CD40L, Flt3 ligand, stem cell factor, ancestim, and TNF ⁇ .
  • Suitable chemokines may include Glu-Leu-Arg (ELR)- negative chemokines such as IP-10, MCP-3, MIG, and SDF-la from the human CXC and C-C chemokine families.
  • Suitable cytokines include cytokine derivatives, cytokine variants, cytokine fragments, and cytokine fusion proteins.
  • a therapeutic agent for use in combination with CD40L expanded TILs for treating cancers as described above may be a cell cycle control/apoptosis regulator (or "regulating agent").
  • a cell cycle control/apoptosis regulator may include molecules that target and modulate cell cycle control/apoptosis regulators such as (i) cdc-25 (such as NSC 663284), (ii) cyclin-dependent kinases that overstimulate the cell cycle (such as flavopiridol (L868275, HMR1275), 7-hydroxystaurosporine (UCN-01, KW- 2401), and roscovitine (R-roscovitine, CYC202)), and (iii) telomerase modulators (such as BIBR1532, SOT-095, GRN163 and compositions described in for instance US 6,440,735 and US 6,713,055) .
  • cdc-25 such as NSC 663284
  • cyclin-dependent kinases that overstimulate the cell cycle such as flavopiridol (L868275, HMR1275), 7-hydroxystaurosporine (UCN-01, KW- 2401), and
  • Non-limiting examples of molecules that interfere with apoptotic pathways include TNF-related apoptosis-inducing ligand (TRAIL)/apoptosis-2 ligand (Apo-2L), antibodies that activate TRAIL receptors, IFNs, and anti-sense Bcl-2.
  • TRAIL TNF-related apoptosis-inducing ligand
  • Apo-2L apoptosis-2 ligand
  • antibodies that activate TRAIL receptors IFNs
  • anti-sense Bcl-2 anti-sense Bcl-2.
  • a therapeutic agent for use in combination with anti-CD40 antibodies for treating cancers as described above may be a hormonal regulating agent, such as agents useful for anti-androgen and anti-estrogen therapy.
  • hormonal regulating agents examples include tamoxifen, idoxifene, fulvestrant, droloxifene, toremifene, raloxifene, diethylstilbestrol, ethinyl estradiol/estinyl, an antiandrogene (such as flutaminde/eulexin), a progestin (such as such as hydroxyprogesterone caproate, medroxy- progesterone/provera, megestrol acepate/megace), an adrenocorticosteroid (such as hydrocortisone, prednisone), luteinizing hormone-releasing hormone (and analogs thereof and other LHRH agonists such as buserelin and goserelin), an aromatase inhibitor (such as anastrazole/arimidex, aminoglutethimide/cytraden, exemestane) or a hormone inhibitor (such as octreotide/
  • a therapeutic agent for use in combination with anti-CD40 antibodies for treating the cancers as described above may be an anti-cancer nucleic acid or an anti-cancer inhibitory RNA molecule.
  • Combined administration, as described above, may be simultaneous, separate, or sequential.
  • the agents may be administered as one composition or as separate compositions, as appropriate.
  • the disclosed anti-CD40 antibodies are administered in combination with radiotherapy. Radiotherapy may comprise radiation or associated administration of radiopharmaceuticals to a patient is provided.
  • the source of radiation may be either external or internal to the patient being treated (radiation treatment may, for example, be in the form of external beam radiation therapy (EBRT) or brachytherapy (BT)).
  • Radioactive elements that may be used in practicing such methods include, e.g., radium, cesium-137, iridium-192, americium-241, gold-198, cobalt-57, copper-67, technetium-99, iodide-123, iodide-131, and indium-111.
  • the disclosed anti-CD40 antibodies are administered in combination with surgery. I.
  • B-cells are frequently found in melanoma metastases, and they display signs of antigen experience and interaction with T-cells.
  • Melanoma infiltrating B-cells express co-stimulatory ligands upon CD40 stimulation, and can present antigen to T cells. Importantly, they do not produce IL-10.
  • Frozen tumor digests grown in presence of CD40 agonists plus IL-2 expand significantly better than with IL-2 alone. From this we conclude that stimulation of B-cells and/or myeloid cells using CD40 agonists enhances the number and quality of ex vivo expanded TIL.
  • we Attorney Docket No: 10110-366WO1 developed a TIL manufacturing process that includes CD40 stimulation during TIL expansion.
  • melanoma tumors contain B cells, which can be activated using a CD40 agonist.
  • Figure 3A shows frozen tumor digests were analyzed for the presence of B cells (CD19+) and myeloid cells (HLA-DR hi ). The vast majority of B cells expressed CD40, while half of myeloid cells did.
  • Figure 3B shows tumor digests were cultured for two days in presence of standard TIL expansion media (Ctrl.) or the same media supplemented with a CD40 agonist (CD40 stim).
  • Figure 13C shows the substitutions of CD40L for variants CD40L_EPC6 (SEQ ID NO: 7), CD40L_EPC1 (SEQ ID NO: 2), CD40L_EPC7 (SEQ ID NO: 6), CD40L_EPC10 (SEQ ID NO: 4) at residues 115- 261 relative to (CD40L_WT)(SEQ ID NO: 1).
  • Figure 14 we next investigated the ability of the variants to activate and bind B cells. We observed no difference in any of the variants to bind and activate B cells. Lastly, we wanted to determine if the mutated monomers can induce TIL expansion to greater rates than standard TIL conditions (control)( Figure 15).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Selon un aspect, sont divulgués de nouveaux monomères CD40L et des procédés d'utilisation desdits monomères, des constructions trimères desdits monomères, et/ou des constructions multimères comprenant lesdits monomères pour étendre des lymphocytes infiltrant les tumeurs (TIL) in vitro ou ex vivo, lesdits procédés comprenant l'obtention de TIL et la culture des TIL dans des milieux comprenant un ou plusieurs agonistes CD40 (tels que, par exemple, un ligand CD40 [CD40L], un anticorps CD40L multimère et/ou un anticorps anti-CD40). Selon certains aspects, l'agoniste de CD40 peut être surexprimé sur une cellule nourricière TIL.
PCT/US2024/031010 2023-05-26 2024-05-24 Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo Pending WO2024249307A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504462P 2023-05-26 2023-05-26
US63/504,462 2023-05-26

Publications (1)

Publication Number Publication Date
WO2024249307A1 true WO2024249307A1 (fr) 2024-12-05

Family

ID=93658643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/031010 Pending WO2024249307A1 (fr) 2023-05-26 2024-05-24 Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo

Country Status (1)

Country Link
WO (1) WO2024249307A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181994A1 (en) * 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20130251752A1 (en) * 2008-03-21 2013-09-26 University Of South Florida Chemokine gene-modified cells for cancer immunotherapy
US20190202892A1 (en) * 2017-12-28 2019-07-04 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
US20210268090A1 (en) * 2018-06-19 2021-09-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050181994A1 (en) * 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US20130251752A1 (en) * 2008-03-21 2013-09-26 University Of South Florida Chemokine gene-modified cells for cancer immunotherapy
US20190202892A1 (en) * 2017-12-28 2019-07-04 Codiak Biosciences, Inc. Exosomes for immuno-oncology and anti-inflammatory therapy
US20210268090A1 (en) * 2018-06-19 2021-09-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand

Similar Documents

Publication Publication Date Title
US12030944B2 (en) Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
TWI793325B (zh) 對cd3具特異性之抗體及其用途
CN116096353A (zh) 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺
US20240307450A1 (en) Treatment of nsclc patients refractory for anti-pd-1 antibody
TWI862870B (zh) 嵌合抗原受體療法t細胞擴增動力學及其用途
WO2021262869A1 (fr) Polythérapie comprenant des anticorps anti-cd137
WO2024249307A1 (fr) Monomères cd40l et leurs procédés d'utilisation dans l'amélioration de til par stimulation ex vivo
AU2024283046A1 (en) Cd40l monomers and methods of their use in til enhancement via ex vivo stimulation
US20240156910A1 (en) Til enhancement via ex vivo stimulation with cd40 agonists
AU2023334022A1 (en) Cd40l 41bbl bispecific proteins
US20220154144A1 (en) Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy
US20240336893A1 (en) Gene signature predicting tertiary lymphoid structures containing b cells
HK40107843A (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
WO2024151885A1 (fr) Utilisation de til en tant que thérapie de maintenance pour des patients atteints de nsclc qui ont atteint une pr/cr après une thérapie antérieure
HK40053266B (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
HK40053266A (en) Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody
HK1257824B (en) Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24816217

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024283046

Country of ref document: AU